

Systems Biology In Biotech & Pharma

[DOWNLOAD HERE](#)

From the contents: ABSTRACT.- 1 INTRODUCTION: DISCOVERY DEVELOPMENT - NEW FACET OF INDUSTRY, NEW TOOLS AND LEAD OPTIMIZATION: 1.1 SCOPE AND CONTENT OF THIS REVIEW.- 1.2 Drug Discovery Development.- 1.3 DEFINING SB: KEY COMPONENTS.- 1.4 A BRIEF HISTORY OF SYSTEMS BIOLOGY (SB), IN TERMS OF KEY ADVANCES.- 1.5 Perspective and Potential Impact of Systems Biology on Academic Funding and Pharma RD Cost Savings.- 2 DISCOVERY: USE OF SYSTEMS BIOLOGY FOR IDENTIFYING TARGETS: 2.1 Identifying Targets Druggability Space.- 2.2 Combinatorial Chemistry Tools.- 2.3 Summarizing.- 3 INTEGRATIVE SYSTEMS BIOLOGY I - BIOCHEMISTRY: PHASE I LEAD DISCOVERY MOLECULAR INTERACTIONS.- 3.1 Molecular Screens: Receptor-Ligand (R-L) Interaction Molecular Modeling.- 3.2 Collateral Efficacy Permissive Antagonism.- 3.3 Co-Drugging: Multiple Targets, Combination Therapy Multistage Targeting.- 3.4 Text Mining For Interactions.- 3.5 Employment of Biochemical Networks.- 3.6 Overview of Deterministic Models.- 3.7 Bioinformatics.- 3.8 Summarizing.- 4 INTEGRATIVE SYSTEMS BIOLOGY II - MOLECULAR BIOLOGY: PHASE 2 LEAD DISCOVERY IN SILICO SCREENING.- 4.1 OMICs.- 4.2 Chemogenomics.- 4.3 Morphogenics.- 4.4 Minimal Phenotype Synthetic Biology.- 4.5 Reconstructing Biological Networks.- 4.6 Summarizing.- 5. DISCOVERY: COMPUTATIONAL SYSTEMS BIOLOGY (CSB) IN HEALTH AND DISEASE I.- 5.1 Cellular Environment: Network Reconstruction Inference from Experimental Data.- 5.2 Reconstructing Gene Networks.- 5.3 Data Mining and heuristic data preprocessing tools.- 5.4 Analysis of Disease Correlation NetworkTM and Concerted Metabolic Activation Disease as a Systems Network Property.- 5.5 Challenges for Stem Cells: Control.- 5.6 Emergent Properties.- 5.7 Computational Systems Biology.- 5.8 Summarizing.- 6 DEVELOPMENT: IN VIVO PHARMACOLOGY - SYSTEMS BIOLOGY IN HEALTH DISEASE II.- 6.1 Animal Disease Models.- 6.2 Pheno- and Genotyping.- 6.3 RNA Interference.- 6.4 Pharmacogenomics (PGN).- 6.5 In silico Pharmacology: Future.- 6.6 Summarizing.- 7 DEVELOPMENT: PHARMACOKINETICS SYSTEMS BIOLOGY IN HEALTH DISEASE III.- 7.1 Microdosing in PK.- 7.2 Adaptive Trial Design.- 7.3 Equilibrium vs. Non-Equilibrium PK Models.- 7.5 Toxicity Biomarkers.- 7.6 In silico Toxicity Prediction.- 7.7 Quantitative PKPD/Tox Modeling.- 7.8

Summarizing.- 8 DEVELOPMENT: MULTISCALE CSB SIMULATION TOOLS.- 8.1 Defining CSB.- 8.2 Redefining (Discovering) Emergent Properties at Higher-Level Hierarchies.- 8.3 Virtual Organs, Disease Models, Virtual Patient.- 8.4 Population Level Model: Towards Individualized Medicine.- 8.5 Targeting Networks: Towards Organismic, Full-Scale Design.- 8.6 Redefining the Traditional RD Paradigm.- 8.7 Summarizing.- 9 DEVELOPMENT: DRUG FORMULATION DELIVERY.- 9.1 Targeting Concept Mechanisms.- 9.2 Nanoscale Drug Delivery Systems.- 9.3 CSB at Formulation Delivery.- 9.4 Summarizing.- 10 DEVELOPMENT: PRECLINICAL MODEL BASED DRUG DEVELOPMENT.- 10.1 Defining MBDD.- 10.2 Summarizing.- 11 SYSTEMS BIOLOGY: IMPACT ON PHARMA AND BIOTECH.- 11.1 SB Impact.- 11.2 Key Technologies and Tools Needed for Development of Systems Biology/CSB.- 11.3 Steps in Systems Biology/CSB.- 11.4 Benefits of Systems Biology and CSB.- 11.5 Summary.- 12 ACKNOWLEDGMENT.- 13 BIBLIOGRAPHY EAN/ISBN : 9789400728493 Publisher(s): Springer, Berlin, Springer Netherlands Format: ePub/PDF Author(s): Prokop, Ale - Michelson, Seth

[DOWNLOAD HERE](#)

Similar manuals: